Akili has unveiled its over-the-counter (OTC) EndeavorOTC digital ADHD treatment, now accessible on Android devices via the Google Play market. This move aligns with Akili's recent transition towards a non-prescription business model, which led to a workforce reduction of around 40%, including the discontinuation of its field sales force and market access team.
EndeavorOTC, rooted in Akili's EndeavorRx technology, was initially launched on the Apple App Store in June. EndeavorRx, a video game designed for children with ADHD, serves as a prescription treatment to enhance attention function. The OTC model aims to provide consumers with a unique, clinically validated technology without the constraints of insurance payers.
Recent clinical trials have demonstrated EndeavorOTC's efficacy in enhancing focus and overall life quality in adults exhibiting ADHD symptoms. Jon David, Akili's Chief Product Officer, emphasized the game's potential to revolutionize ADHD treatment by leveraging the ubiquity of video games in modern culture.
OTC Digital ADHD Treatments
Akili Introduces OTC Digital ADHD Treatment for Android Users
Trend Themes
1. OTC Digital ADHD Treatments - The introduction of OTC digital ADHD treatments opens up new opportunities for individuals seeking alternative solutions for managing their symptoms.
2. Non-prescription Business Model - Akili's transition towards a non-prescription business model creates a disruptive innovation opportunity in the ADHD treatment industry.
3. Clinically Validated Technology - The development of clinically validated technology for ADHD treatment paves the way for more effective and accessible solutions.
Industry Implications
1. Digital Health - The OTC digital ADHD treatment market falls under the digital health industry, offering innovative solutions for mental health support.
2. Gaming - The incorporation of video game elements in ADHD treatment creates opportunities for disruption in the gaming industry.
3. Health Insurance - The shift towards non-prescription models challenges the traditional role of health insurance companies in the ADHD treatment industry.